Publications by authors named "A Jordan Filion"
To achieve replicative immortality, cancer cells must activate telomere maintenance mechanisms. In 10 to 15% of cancers, this is enabled by recombination-based alternative lengthening of telomeres pathways (ALT). ALT cells display several hallmarks including heterogeneous telomere length, extrachromosomal telomeric repeats, and ALT-associated PML bodies.
View Article and Find Full Text PDFArticle Synopsis
- - Anthropogenic changes to landscapes are creating new ecological boundaries that are linked to increased outbreaks of zoonotic diseases, yet the reasons for these new emergence events are not well understood.
- - The study investigates how two types of ecosystem boundaries—biotic transition zones and land use transition zones—affect the risk of disease spillover, using ebolavirus and its reservoir (bats) and accidental host (primates) as a model.
- - Findings reveal that areas where species ranges overlap and where habitat diversity is high increase the risk of ebolavirus outbreaks, while gradual transition zones with rangelands may actually help reduce this risk.
The past few years have been marked by a drastic increase in pathogen spillover events. However, the extent and taxonomic range at which these events take place remain as crucial unanswered questions in many host-pathogen systems. Here, we take advantage of opportunistically sampled bird carcasses from the South Island of New Zealand, with the aim of identifying Plasmodium spp.
View Article and Find Full Text PDFBackground: ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer (mCRC). This study aimed to address gaps in real-world evidence (RWE) including patient characteristics, treatment safety (primary objective), and effectiveness (secondary objective) for first-line ABP 215 therapy in Canadian patients with mCRC.
Materials And Methods: Retrospective data were collected in 2 waves, at least 1 year (Wave 1) or 2 years (Wave 2) after commercial availability of ABP 215 at each participating site.